Its association with cancer recurrence and patient survival suggest that HHLA2 may represent a biologically relevant immune checkpoint molecule in these cancer types and should be evaluated as a potential target for immunotherapy in pancreatic and ampullary cancers. Here, HHLA2 is linked to carcinoma of the ampulla of vater.